Navigation Links
ViroPharma Launches 'HAE and Me,' A New Online Community to Unite People Living With Hereditary Angioedema

EXTON, Pa., March 21, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the launch of "HAE and Me," an online community that unites teens and adults with hereditary angioedema (HAE) through shared experiences to help them better manage their disease.  The website,, features information about HAE, video stories, and first-hand tips from patients, as well as expert advice about living with this rare and potentially life-threatening swelling disease.

"In speaking with patients, we've learned how helpful it is for them to connect with and learn from each other, because one person's experience can inspire countless others," said Kristina Broadbelt, ViroPharma's associate director of global public relations and advocacy.  "'HAE and Me' is designed to address that need by uniting and educating the HAE community and reminding patients that they're not alone."

"HAE and Me" features a dedicated section for "Gen HAE," or teens and young adults with HAE - a patient population with unique needs.  While trying to forge their own identity, a young person with HAE has the added challenge of dealing with a chronic and debilitating disease in which symptoms often begin to manifest or worsen during adolescence.  The content was developed with input from teens with HAE, and focuses on how to overcome common issues and experiences Gen HAE patients may face, like fitting in with their peers, dating, and being involved in extracurricular activities and sports.

"GenHAE" also gives visitors who have questions about navigating life with a rare disease like HAE the opportunity to submit them to Dr. Miriam Kaufman, professor in the Department of Pediatrics at the University of Toronto and the Division of Adolescent Medicine at The Hospital for Sick Children in Toronto.  Dr. Kaufman, a pediatrician who specializes in adolescents with chronic conditions like HAE, has authored a number of books including "Easy For You To Say: Q and A's for Teens Living With Chronic Illness or Disability," focused on topics that matter the most to teens, including family relationships, friends and dating, school and work, and sexuality.

"Being young can be hard enough, but having something that makes you feel different can be truly alienating," said Dr. David Hurewitz, an allergist/immunologist at the Allergy Clinic of Tulsa in Tulsa, Okla.  "Symptoms of HAE often show up for the first time, or get more frequent and severe, during adolescence, leaving young people searching for answers about how to cope.  'Gen HAE' is the only resource of its kind, and I believe can be quite helpful for young people to navigate important issues they may face growing up with HAE."  

"HAE and Me" also links to, the hub for a physician education program that unites disparate specialist organizations to work together to help advance the standard of care for HAE patients, as well as a new documentary film called 'Swell', which showcases the lives of people living with HAE, providing a first-hand look at what it is like to suffer from the disease and how it affects family, friends and loved ones.

About "HAE and Me"

"HAE and Me" is a comprehensive online community that unites people with HAE of all ages through shared experiences to help them better manage their disease.  

The unbranded website,, and the "Gen HAE" section for teens and young adults living with HAE, provide targeted information to people with HAE, including:

  • HAE disease background information, including facts about symptoms, causes, pathophysiology, diagnosing, and managing HAE
  • Video and written profiles of people with HAE and physicians
  • Tips and advice from people with HAE and physicians
  • Quarterly physician spotlights
  • Monthly polls
  • Answers to frequently asked questions about HAE
  • Upcoming events

"Gen HAE," which was developed with input from teens and young adults living with HAE, focuses specifically on the important issues young people growing up with chronic conditions like HAE may face.  Unique to "Gen HAE," visitors can also submit questions to Dr. Miriam Kaufman, a pediatrician who has worked for 27 years with young people who have chronic conditions.  

Information on "HAE and Me" will be regularly updated to include new information and interactive elements, potentially including an interactive map to visually link HAE patients, and a calendar of relevant events around the country.  "HAE and Me" will also expand to include targeted content for other sub-communities of people affected by HAE, such as parents or caregivers.

About Hereditary Angioedema

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at:

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. ViroPharma Announces Securities Repurchase Program
3. ViroPharma to Participate in Two March Healthcare Conferences
4. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
5. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
6. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
7. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
8. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
9. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
10. ViroPharma To Participate in Two September Healthcare Investor Conferences
11. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Post Your Comments:
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):